Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risdiplam in Healthy Japanese Subjects
NCT03040635Phase 1Completed
- Sponsor
- Roche
- Start
- Mar 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of risdiplam in spinal muscular atrophy (SMA) (4 arms), sponsored by Roche. Primary endpoints: Maximum Observed Plasma Concentration, Time to Maximum Plasma Concentration and 10 more. Started Mar 2017; status: completed.
02
Drugs
risdiplam
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT03040635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03040635.